Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Colorcon
Harvard Business School
McKinsey
Mallinckrodt

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR CEDAZURIDINE; DECITABINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Cedazuridine; Decitabine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02103478 ↗ Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) Completed Astex Pharmaceuticals Phase 1/Phase 2 2014-10-28 This first-in-human, 3-stage, open-label study evaluated the safety and pharmacokinetics of ASTX727, as well as determined the dose for later stages.
NCT02103478 ↗ Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) Completed Astex Pharmaceuticals, Inc. Phase 1/Phase 2 2014-10-28 This first-in-human, 3-stage, open-label study evaluated the safety and pharmacokinetics of ASTX727, as well as determined the dose for later stages.
NCT03306264 ↗ Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML Recruiting Astex Pharmaceuticals Phase 3 2018-02-15 Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m^2 Daily×5 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, subjects will continue to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the subject discontinues treatment or withdraws from the study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cedazuridine; Decitabine

Condition Name

Condition Name for Cedazuridine; Decitabine
Intervention Trials
Acute Myeloid Leukemia 13
Myelodysplastic Syndromes 9
Chronic Myelomonocytic Leukemia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cedazuridine; Decitabine
Intervention Trials
Leukemia 17
Myelodysplastic Syndromes 16
Leukemia, Myeloid 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cedazuridine; Decitabine

Trials by Country

Trials by Country for Cedazuridine; Decitabine
Location Trials
United States 92
Canada 7
Germany 4
Spain 3
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cedazuridine; Decitabine
Location Trials
Texas 14
New York 8
Tennessee 5
Maryland 5
California 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cedazuridine; Decitabine

Clinical Trial Phase

Clinical Trial Phase for Cedazuridine; Decitabine
Clinical Trial Phase Trials
Phase 3 1
Phase 2 9
Phase 1/Phase 2 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cedazuridine; Decitabine
Clinical Trial Phase Trials
Not yet recruiting 16
Recruiting 13
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cedazuridine; Decitabine

Sponsor Name

Sponsor Name for Cedazuridine; Decitabine
Sponsor Trials
Astex Pharmaceuticals, Inc. 15
M.D. Anderson Cancer Center 9
National Cancer Institute (NCI) 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cedazuridine; Decitabine
Sponsor Trials
Industry 31
Other 24
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Johnson and Johnson
McKesson
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.